StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Investment analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Up 0.5 %

NYSE:OGEN opened at $0.27 on Monday. Oragenics has a 52 week low of $0.25 and a 52 week high of $3.43. The company has a market capitalization of $3.34 million, a P/E ratio of -0.04 and a beta of 0.38. The stock’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.46.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.